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Tamoxifen and chemotherapy are key treatments for breast cancer patients.
Tamoxifen, an oestrogen antagonist, is a non-steroidal that acts as a selective oestrogen receptor modulator (SERM). It competitively inhibits the interaction of oestrogen with the oestrogen receptor, blocking the effects of E2 and inhibiting receptor activity. Chemotherapy uses cytotoxic drugs to kill cancer cells, by preventing them from multiplying, invading and metastasing. Despite the extensive use of both treatments, failure to respond to them is a major clinical problem and this is the cause of significant morbidity and mortality. To overcome this and to improve patients' treatment options, we need to understand the mechanisms regulating the development of resistance. This study suggests that activation of the Ras pathway predicts for poor outcome on tamoxifen but not chemotherapy, and identifies pRaf(ser338) as a potential marker of resistance to ER-targeted therapy. In addition, it suggests that expression of pRaf(ser338) could identify patients for whom tamoxifen alone is insufficient adjuvant systemic therapy, but for whom the addition of chemotherapy may be of benefit.
Introduction
The Ras/Raf-1/MAPK pathway controls multiple cellular processes, including proliferation, differentiation, senescence and apoptosis (1) . Activation follows membrane tyrosine kinase receptors (EGFR, HER2-4) binding appropriate ligands, dimerising and undergoing autophosphorylation (2, 3) . This activates Ras, which translocates to the plasma membrane and promotes Raf-1 phosphorylation and activation (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . Raf-1 phosphorylates and activates MEK, which activates MAPK, a serine/threonine kinase responsible for phosphorylating and activating substrates, including c-fos and c-myc, which regulate proliferation (14, 15) . MAPK also phosphorylates and activates the oestrogen receptor (ERα) (16) (17) (18) (19) .
Expression and activation of the Ras/Raf-1/MAPK pathway plays an important role in the development and progression of cancer, and may additionally influence response to treatments targeted against ERα and proliferation.
Chemotherapy and endocrine therapy are thought to target proliferating cells, and whilst it remains unclear if highly proliferating tumours are more sensitive to treatment, we hypothesised that activation of this pathway would be an indicator of responsiveness to endocrine and cytotoxic therapies.
The majority of chemotherapeutic agents are thought to function most effectively against proliferating tumour cells in growth phase. Recently the National Epirubicin Adjuvant Trial (NEAT) and BR9601 trial confirmed that the anthracycline, epirubicin, plus CMF, is superior to CMF alone as adjuvant treatment for patients with early breast cancer (22) . Since these agents are more effective against rapidly cycling cells (23), it is feasible that tumours with low proliferative indices may be less sensitive to these therapeutic agents. However, proliferative indices alone are poor predictors of chemotherapeutic response (24).
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Several studies suggest that the Ras/Raf-1/MAPK pathway is linked to response to anthracycline treatment. In vitro Raf-1 (25, 26) and MAPK (27) expression are associated with increased proliferation and anthracycline resistance.
Conversely, increased MAPK activation has been linked to enhanced apoptosis and anthracycline sensitivity (28) . The role of the Ras pathway in determining chemosensitivity therefore requires further investigation.
Activation of Ras/Raf-1/MAPK is also linked to tamoxifen resistance through phosphorylation of ERα. The classic "genomic" action of ERα requires ligand binding, which induces phosphorylation, dissociation from heat shock proteins (Hsps), conformational changes, homodimerisation and nuclear translocation. Nuclear ERα binds to ERE sequences in the promoter region of oestogen regulated genes (29) and recruits co-activators, co-repressors and transcription machinery (16, 30, 31) . ERα can, however, be activated in a ligand-independent manner via signalling pathways.
The Ras/Raf-1/MAPK pathway phosphorylates Serine 118, within the AF-1 domain of the receptor, (16, 18, 19, 32) resulting in its activation and transcription of oestrogenregulated genes and cell proliferation. Consequently, the Ras pathway is thought to increase ERα sensitivity to low concentrations of oestrogen, resulting in tamoxifen resistance (33) (34) (35) . Tamoxifen-resistant cells have been shown to have increased levels of activated MAPK, phosphorylated ERα and transcription of oestrogenregulated genes (36, 37) .
This study investigated whether expression and activation of the key components of the Ras/Raf-1/MAPK pathway influenced clinical outcome, to test the hypothesis that activation of the pathway drives resistance to tamoxifen and chemotherapy in clinical breast cancer. In order to achieve this two different patient groups were used, a tamoxifen treated and a chemotherapy treated cohort. The study 7 population included ER+ve patients who received tamoxifen treatment alone and in combination with chemotherapy, and patients from the Scottish BR9601 trial who received either CMF or sequential epirubicin followed by CMF.
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Materials & Methods
Patient Cohorts
Two patient cohorts were studied, after obtaining ethical approval for each study separately. The first comprised 402 patients with ERα positive tumours who were treated at Glasgow Royal Infirmary between 1980-1999 (Steroid Resistant Tumour Bank -STB). These patients received adjuvant tamoxifen for a median of 5 years (range 0.6-18 years) and follow-up data was available for a median of 6.45 years (range 0.64-18.42 years). In addition, 99 (24.8%) of these patients received adjuvant chemotherapy and 110 (27.5%) received adjuvant radiotherapy. ERα status was defined as previously described (38) . Clinical/pathological characteristics for these patients are shown in Table 1 . In this study there were 74 breast cancer specific deaths and 100 breast cancer relapses, 78 of which occurred during tamoxifen treatment.
An additional 318 patients were studied, from the BR9601 adjuvant chemotherapy trial designed to test the possible benefit of 4 cycles of epirubicin followed by 4 cycles of CMF over 8 cycles of CMF chemotherapy in women with early breast cancer. There was a median follow up of 4.95 years (range 0.27-8.52 years), with 84 breast cancer related deaths and 111 breast cancer recurrences (both local and distant). Clinical/pathological characteristics are again shown in Table 1 .
Antibodies
Ras protein expression was investigated using three isoform specific antibodies: HRas (IgG 1 Ab, F235, Santa Cruz, CA, USA); K-Ras (Sigma, Dorset, UK) and N-Ras (IgG1 Ab, F155, Santa Cruz). Raf-1 protein expression was measured using a Raf-1 antibody (IgG1 Ab, E-10, Santa Cruz) and two phospho-specific antibodies recognising active and inactive Raf-1: phospho-Raf(ser338) (Upstate, CA, USA) and phospho-Raf(ser259) (Cell Signalling Technology, MA, USA; CST), respectively. MAPK expression was investigated using a p44/42MAPK antibody (CST) and a phospho-specific p44/42 MAPK(Thr202/Tyr204) antibody (CST). All Ras antibodies were used at a concentration of 20µg/ml; the Raf-1 antibody was used at 5µg/ml, the phospho-Raf-1 antibodies at 4µg/ml, and both MAPK antibodies at 0.5µg/ml in antibody diluent (DAKO, Glostrup, Denmark) for immunohistochemistry. All antibodies were used to investigate protein expression in the STB study but only pRaf(ser259), pRaf(ser338), MAPK and pMAPK antibodies were used in the BR9601 study. The specificity of all antibodies was confirmed by western blotting.
Western Blotting
Proteins from unstimulated and 10nM Heregulin (HRG) stimulated MCF-7 and 
TMA Construction
Tissue microarrays (TMA) were constructed for 402 ERα positive STB tumours and the 318 BR9601 breast tumours (39) . TMA construction allows rapid tumour processing under standardised conditions and has been extensively validated in breast cancer. Up to 100-200 (0.6 diameter) individual tumour cores were placed into a single recipient block enabling simultaneous multiple tumour analysis. A consultant breast pathologist was responsible for marking tumour areas on haematoxylin and eosin stained tumour slides prior to coring. To account for tumour heterogeneity, 3* 0.6 mm cores were removed from the marked areas in each tumour block and transferred to recipient paraffin blocks to form the TMA.
Immunohistochemistry
IHC for H-Ras, N-Ras and Raf-1 was performed as previously described (40) . For pRaf(ser338) and K-Ras, antigen retrieval was performed by heating under pressure in 
Histoscore Method
Two observers (LM & TK) trained by a pathologist, independently scored tumour cores, as selected by a pathologist, using a weighted histoscore method (41, 42) . The intensity of cytoplasmic and nuclear staining was categorised as negative (0), weak (1), moderate (2) and strong (3) 
Statistical Analysis
Statistical analysis was performed using the SPSS statistical package (version 9.0 for Windows). Correlations between proteins were calculated using the Spearman Rank Test. Pearsons chi-square test was used to correlate protein expression with known prognostic factors. Kaplan-Meier life-table analysis and Cox's multiple regression (including known prognostic factors tumour size, grade and nodal status) were performed to estimate differences in breast cancer related survival, in terms of disease-free survival (DFS) and overall survival (OS), using breast cancer recurrences and breast-cancer specific deaths as the respective end-points. To establish the relative risk of a patient relapsing or dying as a result of either high or low levels of a particular protein in their breast tumour, hazard ratio analysis was calculated by Cox's multiple regression using only the protein of interest as a variable. For survival analysis and chi-square tests, patients were split into two groups, those that expressed 12 high levels of protein and those that expressed low levels. For all proteins analysed, high levels were defined as IHC scores equal to or above the upper quartile value, whilst low levels were defined as IHC scores less than the upper quartile value. A value of p<0.05 was deemed statistically significant.
Results
Patient cohort & treatment
Of 402 STB patients, 303 individuals received tamoxifen alone, whilst the remaining 99 received both tamoxifen and chemotherapy. Survival analysis was performed on the entire cohort but also on the subgroup of patients who received only tamoxifen, thus addressing the potential confounding effects of both endocrine and chemotherapy treatments. Patients from the BR9601 trial were randomly allocated to receive either CMF alone or epirubicin followed by CMF. Three hundred and eighty four patients were randomised in BR9601 and tissue samples retrieved from 318 cases (84%). One hundred and fifty five (49%) patients received treatment with epirubicin followed by CMF while the remaining 163 (51%) patients received only CMF. Additionally, 165 of the BR9601 patients received tamoxifen. A survival analysis of those patients whose samples contributed to this sub-study confirmed the statistical advantage of Epi-CMF over CMF observed in the main BR9601 and NEAT studies (43) (data not shown).
Protein Expression
H-, K-and N-Ras and Raf-1 expression was investigated in the STB cohort, whilst the inactivated and activated form of Raf-1, pRaf(ser259) and pRaf(ser338) respectively, and MAPK and pMAPK, were analysed in both the STB and BR9601 cohort of patients. With the exception of pRaf(ser259), which was localised primarily to the cytoplasm, all proteins were expressed in both the cytoplasm and nuclei of tumour cells ( Figure 1, Table 2 ). Despite the high frequency of patients expressing both cytoplasmic and nuclear H-K-and N-Ras, there was no significant relationship between the expression levels of Ras in the two locations. However, a strong positive 14 correlation was evident between the cytoplasmic and nuclear localisation of Raf-1, pRaf(ser338), MAPK and pMAPK.
Activation of the Ras/Raf-1/MAPK pathway in breast tumours
Tumours from the STB and NEAT cohorts with elevated activated Raf, pRaf(ser338), also expressed increased levels of cytoplasmic and nuclear pMAPK (Spearman's rank test; Table 3 ). In the STB study, overexpression of Ras isoforms was associated with increased activated Raf expression; N-Ras was most markedly correlated with pRaf (p<0.0005, CC = 0.274, Table 3 ).
Protein expression and association with known prognostic markers
In the STB cases nuclear pRaf(ser338) expression was positively correlated with node positivity (p=0.009), elevated expression of cytoplasmic pRaf(ser338) was associated 
BR9601 survival analysis
Survival analysis revealed no significant association between tumour expression of pRaf(ser259), pRaf(ser338), MAPK or pMAPK and risk of breast cancer recurrence or death in BR9601 patients receiving chemotherapy (Epi/CMF or CMF) either alone or with tamoxifen.
ER positive tamoxifen only treated cases (303 STB cases) survival analysis
In the 303 STB cases treated only with tamoxifen, patients with tumours overexpressing cytoplasmic (p=0.0023, 10.2 years versus 13.3 years) or nuclear pRaf(ser338) (p=0.002, 10.3 years versus 12.8 years) had worse DFS (Figure 3a,b) .
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The relative risks for relapse associated with increased expression of cytoplasmic or nuclear pRaf(ser338) were 2.02 (95% CI 1.27-3.21, p=0.0028) and 2.08 (95% CI Survival analysis demonstrated that increased expression of cytoplasmic and nuclear pRaf(ser338) was associated with increased risk of relapse and death in the 303 tamoxifen only treated patients and on multivariate analysis nuclear pRaf(ser338) expression was independent of nodal status, tumour size and grade (p=0.031). In addition, elevated levels of cytoplasmic and nuclear pMAPK were associated with an increased risk of recurrence in this patient cohort. Conversely, in the 264 ERα positive patients treated with both chemotherapy and tamoxifen, no association with phosphorylated Raf-1 or MAPK was observed with patient outcome measures.
These results suggest that increased Raf-1/MAPK phosphorylation, or activation is associated with early relapse on adjuvant tamoxifen and that nuclear pRaf(ser338) is a candidate for identifying ERα positive patients at risk of relapse if treated with tamoxifen alone. We cannot at present, rule out the possibility that pRaf(ser338) functions as a prognostic marker, as opposed to predictive marker, since all cases analysed received adjuvant therapy, however it appears to function at least additionally as a predictive factor for improved benefit from chemotherapy. In the 99 STB patients who received both adjuvant tamoxifen and chemotherapy, it seemed that the addition of chemotherapy increased the time to relapse in those patients expressing high levels of pRaf(ser338). Interestingly, pRaf(ser338) was not an independent predictor of tamoxifen resistance when the 303 tamoxifen only and 99 tamoxifen and chemotherapy treated patients were combined. This suggests that chemotherapy partially overrides the negative effects of increased expression of nuclear pRaf(ser338). Increased tumour levels of pRaf(Ser338) are perhaps indicative of decreased benefits from tamoxifen but enhanced response to chemotherapy. This supports previous findings that increased expression of Raf-1 in cell lines makes them more responsive to chemotherapeutic agents (44) . To confirm this hypothesis, ideally analysis of an untreated patient cohort would be undertaken to address any potential prognostic role and to determine if pRaf(ser338)is also a predictive marker in the context of benefit associated with tamoxifen therapy.
Raf-1 is a serine-threonine kinase that plays a role in cell proliferation, differentiation and apoptosis, and is prominent in controlling tumour angiogenesis and metastasis (45, 46) . We show that increased Raf-1 activity in tumours was related to poorly differentiated tumours (high grade) and tumour spread (node positivity). A recent study demonstrated that targeting Raf-1 inhibits tumour growth and that this represents an important therapeutic strategy (47).
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The ligand-independent phosphorylation of ERα at serine 118 by MAPK is believed to be a major contributor to the development of tamoxifen resistance and this relationship between the Ras/Raf-1/MAPK pathway and ERα has been well documented. It is hypothesised that phosphorylation of ERα contributes to tamoxifen resistance by promoting tumour growth in the presence of low levels of oestrogen (48, 49) . However in the current study nuclear pRaf(ser338) appears to be dominant over MAPK, which implies that whilst MAPK driven phosphorylation of ERα may be important, it is not the only contributing factor in the development of tamoxifen resistance. It also suggests that the mechanism by which nuclear pRaf(ser338) influences tamoxifen resistance is independent of MAPK.
In summary, this study demonstrates that expression and activation of the Ras/Raf-1/MAPK pathway in breast tumours is associated with increased risk of relapse and death with tamoxifen treatment but not when chemotherapy is also given to ERα positive cases. These results suggest that activated Raf-1 is a potential predictive marker for identifying patients who are least likely to benefit from tamoxifen and for whom additional therapy may be required. Table 2 shows the median histoscore and interquartile range (IQ) for protein expression in the cytoplasm and nuclei of breast tumour cells. 
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